Equasens Group reported a decline in revenue and profit margins for 2024, but remains committed to growth
From GlobeNewswire: 2025-03-28 13:00:00
Equasens Group reported its 2024 annual results, with revenue at €216.8m (-1.4%), Current Operating Income at €45.1m (-19.2%), and Net profit at €36.2m (-23.0%). The profit margins remained high, with a solid balance sheet structure and an annual dividend proposal of €1.25 per share. The company plans to return to revenue growth of close to 10% by the end of 2025, deploying new AI solutions and cloud services while maintaining a strategy of external growth in France and Europe.
The Board of Directors of Equasens Group approved the financial statements for 2024, showcasing revenue decline and lower profit margins in various divisions. The Pharmagest Division saw a contraction in earnings due to weaker sales, while the Axigate Link Division maintained a high rate of profitability. The E-CONNECT division experienced lower sales but managed to control costs, and the Medical Solutions Division focused on transitioning to new software solutions, impacting profitability.
Despite challenges in various divisions, Equasens Group remains committed to innovation and AI integration to drive revenue growth in 2025. The company’s strategic focus includes transitioning to a SaaS business model, deploying high-value solutions, and maintaining patient-focused strategies for better healthcare outcomes. While profitability may be impacted by ongoing investments, Equasens Group aims to deliver innovative offerings to customers for sustainable growth.
The company’s financial calendar includes key dates like the presentation of FY 2024 results on March 31, 2025, the Annual General Meeting on June 25, 2025, and the publication of Q1, Q2, and H1 results in 2025. Equasens Group, a leader in digital healthcare solutions, employs over 1,300 people across Europe. The Group focuses on developing specialized applications to support healthcare professionals and improve patient care through innovative technology solutions.
Equasens Group’s financial surplus remains strong at €79.5m, supporting its investment capacity and growth strategy. The Board of Directors will propose a gross dividend of €1.25 per share for fiscal 2024. Forward-looking statements indicate the company’s commitment to innovation and growth, despite potential risks and uncertainties in the operating environment.
Read more at GlobeNewswire:: Equasens: 2024 annual results